Company intelligence / Profile preview

Vikel

San Diego, California, United Statesvikelonline.com ↗

Ownership: Private
Employees: ~120
Development stage: Other

Overview

Vical developed biopharmaceutical products using its proprietary DNA delivery platform. Its most advanced program was Allovectin-7®, an immunotherapeutic for metastatic melanoma that reached a pivotal Phase 3 trial. Another key program was a cytomegalovirus DNA vaccine in Phase 2 trials for stem cell transplant recipients. The company also explored vaccines for pandemic influenza and other infectious diseases. Clinical results were mixed; Allovectin failed to meet endpoints in its pivotal trial.

Therapeutic areas: CardiovascularOncologyInfectious Diseases
Modalities: DNA vaccineDNA immunotherapeuticSmall molecule
Industry: Biotech

Partnerships

Collaborated with major pharmaceutical companies and biotechnology firms to access complementary technologies or resources; specific partners not named in provided sources

Beyond the preview

Go deeper on Vikel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vikel.

Explore the full profile